Top Tweets for #PLENARY
Last week, SOuRCe was excited to attend the 2026 #Annual #ARCS #Conference in #Sydney! This was an engaging event with #interactive #workshops and #plenary #discussions on #clinical #research, a huge thank you to @cancerNSW for sponsoring SOuRCe to attend!
@SydneyLHD #ARCS2026
🇪🇺💺 The MEPs and the @Europarl_EN staff are on the trains to #Strasbourg!
These are the highlights of a new, busy #plenary session week at the #EuropeanParliament, in the official seat of the Assembly.
Which one is the most important to you?
#EU #EP #ThisIsTheEU #politics
Which is better for Rx autoimmune dz…Deeper B cell depletion vs breadth of B cell depletion? #Plenary #EULAR2026
#Anifrolumab for #Sjogren. Small RCT study noted improved CRESS, cSTAR, ESSPRI, ESSDAI. No issues with safety, no change in histology score, but MxA expression reduced in ANI group #EULAR26 #Plenary @RheumNow
We are thrilled to announce that Dr Soumya Swaminathan will deliver a #plenary #lecture at the #IUBSGA2026
🗓️ 10th June 2026
📍 JN Tata Auditorium, IISc, Bengaluru, India
🔗https://t.co/4XbAuqoDOk
@doctorsoumya
@DBTIndia @ANRFIndia @CSIR_IND @BeSTCluster
#onehealth
#ASCO26 @ASCO
Daraxonrasib in pretreated PDAC RASolute302 #Plenary
So deserving of the standing O 👏 👏 👏
Excellent & passionate discussion by Dr. Jennifer Knox with a Call to Action…and, in the words of Dr. Brian Wolpin, a Call to Science 💜
#TimeIsNow
🔥🚨@OncoAlert Hot off the press.
Just presented @ASCO #ASCO26 (#Plenary Presentation) by Dr. Shun Lu.
⭐️#OverallSurvival Results of:
❇️#HARMONi6 trial of:
#Ivonescimab + #Chemo Vs
#Tislelizumab + #Chemo
For #1st line Tx of Advanced #Squamous Non-Small-Cell #LungCancer.
✅#Significant Improvement in #OS
⬆️#mOS 27.9 vs 23.7 mo (HR 0.66)
✅Benefit in PD-L1 <1% & PD-L1 ≥1%
📣Results published simultaneously @TheLancet (See tweet/post below👇🏻)
🔥🚨@OncoAlert Hot off the press.
Just published @TheLancet In conjunction with #plenary presentation @ASCO #ASCO26.
⭐️#OverallSurvival Results of ❇️#HARMONi6 trial of:
#Ivonescimab + #Chemo Vs
#Tislelizumab + #Chemo
For #1st line Tx of Advanced #Squamous Non-Small-Cell #LungCancer
✅#Significant Improvement in #OS
⬆️#mOS 27.9 vs 23.7 mo (HR 0.66)
👇🏻
https://t.co/6iJiPmFw9N
🔥🚨@OncoAlert Hot off the press.
Just presented @ASCO #ASCO26 (#Plenary Presentation) by Dr. Jonathan Goldman.
⭐️Results of #PracticeChanging #LIBRETTO432 Trial of:
#Adjuvant #Selpercatinib vs #Placebo
in Early-Stage (IB-IIIA) #RET+ Non-Small-Cell #LungCancer.
✅⬆️#EFS
❇️#HR: 0.17 for stage II-IIIA
2-year EFS: 92% vs 61%
❇️#HR: 0.16 for stage IB-IIIA
2-year EFS: 94% vs 70%
🎯‼️#NEW #StandardOfCare
📣Results published simultaneously @NEJM (See tweet/post below👇🏻)
🔥🚨@OncoAlert Hot off the press.
Just published @NEJM In conjunction with presentation @ASCO #ASCO26.
⭐️Results of #PracticeChanging #LIBRETTO432 Trial of:
#Adjuvant #Selpercatinib vs #Placebo
in Early-Stage (IB-IIIA) #RET+ Non-Small-Cell #LungCancer.
✅⬆️#EFS
❇️#HR: 0.17 for stage II-IIIA
2-year EFS: 92% vs 61%
❇️#HR: 0.16 for stage IB-IIIA
2-year EFS: 94% vs 70%
🎯‼️#NEW #StandardOfCare
👇🏻
https://t.co/u6PLyTLCqr
🔥🚨‼️🎯 @OncoAlert #BreakingNews Hot off the press.
⭐️⭐️‼️‼️Every #Oncologist HAS TO BE SO EXCITED for #Patients when a #PancreasCancer #Treatment #DOUBLES Median #OverallSurvival.
📣Just published @NEJM In conjunction with #plenary presentation @ASCO #ASCO26.
❇️Results of #RASolute302 trial of:
#Daraxonrasib vs #Chemo in Previously
Treated Metastatic #PancreaticCancer with #RAS/#G12
👇🏻
https://t.co/vT91FbEd6r
🔥🚨@OncoAlert Hot off the press.
Just published @TheLancet In conjunction with #plenary presentation @ASCO #ASCO26.
⭐️#OverallSurvival Results of ❇️#HARMONi6 trial of:
#Ivonescimab + #Chemo Vs
#Tislelizumab + #Chemo
For #1st line Tx of Advanced #Squamous Non-Small-Cell #LungCancer
✅#Significant Improvement in #OS
⬆️#mOS 27.9 vs 23.7 mo (HR 0.66)
👇🏻
https://t.co/6iJiPmFw9N
A thrill to be at #ASCO26 where the best in #GIonc will be presented. To have an earth shattering #plenary with #RASOLUTE will be a dream come true but many other highlights #Fight302 🥊 #Emerald3 💎 #PUMP ⛽️ #BREAKWATER 🌊. So much to love!
#OncoAlertAF
@FadiHaddad_MD
@Abdallah81MD
@Erman_Akkus
@bavilima
@acampsmalea
@DrFMartinelli
@Dr_Ivanoncologo
@orellanauro
@FernandoOnco
@Lucarecco
@HHorinouchi
@ElisaAgostinett
@to_be_elizabeth
@BRicciutiMD
@nataliagandur
@GaiaGriguolo
@JankovicK
@weoncologists
@OncoReporte
@GIMedOnc
@MarioBalsaMD
@DrMirallas
@OscarTahuahua
@DrRishabhOnco
@UOzkerim
@Onco_Cifu88
@DraMartinezLago
@DaisukeKotani
The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more
A snapshot of what will shape GI oncology at #ASCO26 👇
🚨 OncoAlert Top 10 — #GIcancer at #ASCO26
1️⃣ LBA5 | RASOLUTE 302 — Daraxonrasib vs chemo in previously treated metastatic pancreatic adenocarcinoma
2️⃣ #4017 | FIGHT-302 — Pemigatinib in untreated unresectable/metastatic FGFR2-rearranged cholangiocarcinoma (Ph3)
3️⃣ LBA4000 | EMERALD-3 — Tremelimumab + durvalumab + lenvatinib + TACE in unresectable HCC (Ph3)
4️⃣ #3506 | PUMP Trial — Adjuvant HAIP floxuridine in resectable colorectal liver metastases
5️⃣ LBA3500 | CIRCULATE — ctDNA-guided adjuvant therapy in Stage II colon cancer
6️⃣ LBA3503 | BREAKWATER — Encorafenib + cetuximab + FOLFIRI as 1L in BRAF V600E mCRC (Ph3)
7️⃣ LBA3508 | EPISODE-III — Adjuvant aspirin vs placebo in Stage III CRC post-resection (Ph3)
8️⃣ #3505 — Trastuzumab rezetecan vs SOC in chemo-refractory HER2+ advanced CRC (Ph3)
9️⃣ #4006 | ATTRACTION-6 — Nivo + ipi + chemo as 1L in HER2− advanced gastric/GEJ cancer
🔟 #3504 | SWOG S2107 — Encorafenib + cetuximab + nivo in MSS BRAF V600E mCRC (Ph2)
Leads
@realbowtiedoc
@p_ciracimd
@WeOncologists
Senior faculty
@CathyEngMD @ARosen380 @GillSharlene @BenWestphalen @graokane
Participating AF
@DrVilmaPBarcia @Erman_Akkus @GIMedOnc
Speaker of parliament Oboth oboth has today officially closed the orientation of members of 12th parliament committing to functional parliamentary committees and emphasizing people's centred parliament. #GoldenPosts #plenary
Ladies and gentlemen, Hon. Oboth Oboth is in the House, and so far the start has been good. I am convinced that he has fulfilled his pledge during swearing-in: he will be a Speaker for all MPs, including NRM, Opposition, and Independents.#GoldenPosts
#plenary
What is scholarly impact? How can we measure it? Join us at this #plenary panel at the @AACSB + @AOMConnect conference in #Dublin, #Ireland, next week.
In 1975, Steven Kerr published a highly influential article. His argument was deceptively simple: Organizations routinely reward one behavior while hoping to get another. For example, soldiers in Vietnam were rewarded for completing their tour of duty regardless of whether the war was won, so they behaved accordingly. Insurance clerks were rewarded for showing up on time rather than for accuracy, so accuracy suffered. The mechanism in each case was identical: The performance measurement and reward system was designed for one purpose, but applied to produce a completely different outcome. Half a century later, business schools are committing the same folly, but not with soldiers or insurance clerks, but with how scholarly impact is measured and rewarded. We publish thousands of peer-reviewed articles on how to measure performance fairly, how to motivate people effectively, and how to align reward systems with strategic goals. So, we can, and should, do better.
Read the article: https://t.co/7lWz5WqV1R
@AIB_LAC @AIB_World @anzam_news @AOM_CTO @AOM_HCM @AOM_OB @AOM_ONE @AOM_SIM @AOM_STR @AOM_TIM @AOMDEI @bam_ac_uk @cms_aom @EasternAoM @EFMDNews @ENT_Div_AoM @EURAM_BXL @GWAlumni @GWAlumniChicago @GWAlumniWeekend @GWAlumniofSoCal @GWArgentina @GWBAA @GWEnergyAlumni @gwbusiness @GW_OVPR @GWSBalumni @GWtech @GWtweets @HR_Div_AoM @IberoAoM @ICSB @IIAS_IISA @MFCAinc @mh_aom @MOC_AOM @MOCDivision @presidentofGW @RMD_AOM @SIOPtweets @SouthernMgt @Strategic_Mgmt @SWAcademyOfMGMT @ThePhDProject @EFMDNews @efmdamericas
It’s a full house as the 11th Parliament holds its final plenary, with MPs set for the crucial second and third readings of the controversial Sovereignty Bill. #COUFamilyTV #Plenary
📷:@Parliament_Ug
Hon. Ssemujju Nganda: The last time the SFC invaded us they were standing like @NRMOnline Mps who are standing in the corners there.
If they don't mind they can move out and we get some fresh air we shall call them when voting starts. @Parliament_Ug
#COUFamilyTv #plenary
📷:CC
Last Seen Hashtags on Sotwe
adambenchakroun
OpenRafahCrossing
Seen from United States
เมียเพื่อน
Seen from Thailand
transfem
Seen from United States
mersinbayan
Seen from Turkey
อวบน่าเย็ด
Seen from Thailand
foodie
Seen from United States
omegle video
Seen from South Africa
nolimit nolimit
Seen from United States
tommavi lang:it
Seen from Italy
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.6M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.2M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.5M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69.1M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.8M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.3M followers